Byong Chul Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Byong Chul Yoo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Kyung-Hee Kim
Department of Applied Chemistry, School of Science and Technology, Kookmin University, Seoul 02707, Republic of Korea
17 shared publications - Hwa-Seung Yoo
East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University
2 shared publications - Tae-Kyung Yeo
Oculi Korean Medicine Hospital, Seoul 05655, Republic of Korea
2 shared publications Dong Seon Kim
Department of Integrative Biotechnology, Sungkyunkwan University
1 shared publicationHwa Pyoung Lee
Department of Integrative Biotechnology, Sungkyunkwan University
1 shared publicationHyoung-June Kim
Research and Innovation Center, AMOREPACIFIC
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15  (11) , 1469
Lipoprotein-Delivered Antioxidants in Cancer: An Extracellular Supply Route to Ferroptosis Resistance
Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation. Some therapy-resistant cancer cells remain vulnerable to this process, creating interest in disrupting the defenses that prevent membrane oxidation. This review critically examines how lipoprotein-derived α-tocopherol contributes to ferroptosis resistance and how its protective effects can be distinguished from lipid remodeling and intracellular antioxidant compensation. We integrate evidence on circulating antioxidant carriers, glycosaminoglycan-dependent uptake, and scavenger receptor class B type 1-mediated delivery, including regulation by mechanistic target of rapamycin complex 1. We compare the experimental support and limitations of these mechanisms and consider how tissue environments alter antioxidant availability and defense requirements. The available evidence supports extracellular α-tocopherol acquisition as an additional layer of ferroptosis protection in selected experimental cancer models; its prevalence and therapeutic importance in human tumors remain unresolved. Establishing dependence requires cargo-specific measurements, controlled uptake perturbations, membrane lipid analysis, and confirmation of ferroptotic death. Therapeutic targeting will require functional biomarkers and evidence that restricting antioxidant supply compromises tumor survival within a tolerable therapeutic window.
- 12 November 2026
- Published by MDPI AG in Antioxidants
- Vol. 15  (11) , 1469
Open AccessLipoprotein-Delivered Antioxidants in Cancer: An Extracellular Supply Route to Ferroptosis Resistance
Ferroptosis is an iron-dependent form of regulated cell death driven by phospholipid peroxidation. Some therapy-resistant cancer cells remain vulnerable to this process, creating interest in disrupting the defenses that prevent membrane oxidation. This review critically examines how lipoprotein-derived α-tocopherol contributes to ferroptosis resistance and how its protective effects can be distinguished from lipid remodeling and intracellular antioxidant compensation. We integrate evidence on circulating antioxidant carriers, glycosaminoglycan-dependent uptake, and scavenger receptor class B type 1-mediated delivery, including regulation by mechanistic target of rapamycin complex 1. We compare the experimental support and limitations of these mechanisms and consider how tissue environments alter antioxidant availability and defense requirements. The available evidence supports extracellular α-tocopherol acquisition as an additional layer of ferroptosis protection in selected experimental cancer models; its prevalence and therapeutic importance in human tumors remain unresolved. Establishing dependence requires cargo-specific measurements, controlled uptake perturbations, membrane lipid analysis, and confirmation of ferroptotic death. Therapeutic targeting will require functional biomarkers and evidence that restricting antioxidant supply compromises tumor survival within a tolerable therapeutic window.
- Open Access
- 8 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (18) , 7996
Targeting Cancer Hallmarks with Cirsium japonicum: Molecular Mechanisms and Therapeutic Potential
Cirsium japonicum is a medicinal plant traditionally used in East Asian medicine and contains multiple bioactive constituents with potential anticancer properties. This review critically evaluates the anticancer effects of C. japonicum and its associated constituents within the Hallmarks of Cancer framework. Evidence was classified as direct plant-specific evidence, constituent-based evidence, or contextual mechanistic evidence to distinguish findings obtained using botanical preparations from those generated using purified compounds derived from other sources. Direct studies of C. japonicum extracts, flavonoid fractions, phenylpropanoid glycosides, and C. japonicum var. maackii-mediated gold nanoparticles demonstrate antitumor, cytotoxic, antiangiogenic, immunomodulatory, and ferroptosis-associated activities, although target-level validation remains limited. Among its associated constituents, pectolinarigenin has the most developed mechanistic evidence, involving RRM2–CDK1, TOP2A, STAT3, and PI3K/AKT/mTOR signaling. Apigenin, luteolin, acacetin, linarin, cirsimaritin, and pectolinarin additionally influence regulated cell death, proliferative signaling, angiogenesis, metastasis, immune regulation, metabolic vulnerability, senescence, and therapy response. However, much of this evidence relies on pathway-associated changes rather than direct target engagement or genetic validation. Furthermore, the pharmacokinetics, systemic exposure, botanical standardization, tumor selectivity, and clinical relevance of these compounds remain insufficiently characterized. Future studies should prioritize standardized preparations, quantitative exposure analysis, functional target validation, clinically relevant models, and carefully designed combination strategies. Collectively, C. japonicum provides a promising multi-hallmark framework for anticancer investigation, but substantial translational evidence is still required before its therapeutic potential can be established.
- 8 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (18) , 7996
Open AccessTargeting Cancer Hallmarks with Cirsium japonicum: Molecular Mechanisms and Therapeutic Potential
Cirsium japonicum is a medicinal plant traditionally used in East Asian medicine and contains multiple bioactive constituents with potential anticancer properties. This review critically evaluates the anticancer effects of C. japonicum and its associated constituents within the Hallmarks of Cancer framework. Evidence was classified as direct plant-specific evidence, constituent-based evidence, or contextual mechanistic evidence to distinguish findings obtained using botanical preparations from those generated using purified compounds derived from other sources. Direct studies of C. japonicum extracts, flavonoid fractions, phenylpropanoid glycosides, and C. japonicum var. maackii-mediated gold nanoparticles demonstrate antitumor, cytotoxic, antiangiogenic, immunomodulatory, and ferroptosis-associated activities, although target-level validation remains limited. Among its associated constituents, pectolinarigenin has the most developed mechanistic evidence, involving RRM2–CDK1, TOP2A, STAT3, and PI3K/AKT/mTOR signaling. Apigenin, luteolin, acacetin, linarin, cirsimaritin, and pectolinarin additionally influence regulated cell death, proliferative signaling, angiogenesis, metastasis, immune regulation, metabolic vulnerability, senescence, and therapy response. However, much of this evidence relies on pathway-associated changes rather than direct target engagement or genetic validation. Furthermore, the pharmacokinetics, systemic exposure, botanical standardization, tumor selectivity, and clinical relevance of these compounds remain insufficiently characterized. Future studies should prioritize standardized preparations, quantitative exposure analysis, functional target validation, clinically relevant models, and carefully designed combination strategies. Collectively, C. japonicum provides a promising multi-hallmark framework for anticancer investigation, but substantial translational evidence is still required before its therapeutic potential can be established.
- Open Access
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (17) , 7717
From Claims to Evidence: Re-Evaluating the Molecular Pharmacology of Cirsium japonicum
Cirsium japonicum Fisch. ex DC. has long been used in traditional East Asian medicine and has attracted increasing attention because of its diverse pharmacological activities, including antioxidant, anti-inflammatory, antifibrotic, metabolic regulatory, and anticancer effects. Although numerous studies have investigated its phytochemical composition and biological activities, current evidence has largely been organized according to individual compounds or disease categories, providing limited insight into the shared molecular mechanisms underlying its pleiotropic actions. In this review, we critically re-evaluate the molecular pharmacology of C. japonicum using an evidence-oriented framework that distinguishes experimentally supported mechanisms from pharmacological associations and emerging hypotheses. Rather than accepting changes in signaling proteins or downstream biomarkers as sufficient evidence of mechanism, we assess the strength of evidence based on reproducibility, pathway-specific interventions, genetic or pharmacological validation, and direct target engagement. Current evidence indicates that nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant responses and nuclear factor kappa B (NF-κB)-associated inflammatory responses represent the most consistently observed pathway associations, although direct molecular targets and causal pathway dependency remain insufficiently established. Evidence for AMPK/PI3K-Akt-associated metabolic regulation and TGF-β/Smad-associated antifibrotic responses is comparatively more limited. In contrast, modulation of apoptosis and autophagy is currently supported primarily by indirect or context-dependent observations. We further discuss how multiple phytochemicals converge on interconnected signaling networks regulating oxidative stress, inflammation, metabolism, tissue remodeling, and cell fate, thereby providing a systems-level explanation for the broad therapeutic potential of C. japonicum. Finally, we highlight the need for standardized phytochemical characterization, rigorous target validation, multi-omics integration, and artificial intelligence-assisted systems biology to establish causal molecular mechanisms and accelerate the translational development of evidence-based phytopharmaceuticals.
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (17) , 7717
Open AccessFrom Claims to Evidence: Re-Evaluating the Molecular Pharmacology of Cirsium japonicum
Cirsium japonicum Fisch. ex DC. has long been used in traditional East Asian medicine and has attracted increasing attention because of its diverse pharmacological activities, including antioxidant, anti-inflammatory, antifibrotic, metabolic regulatory, and anticancer effects. Although numerous studies have investigated its phytochemical composition and biological activities, current evidence has largely been organized according to individual compounds or disease categories, providing limited insight into the shared molecular mechanisms underlying its pleiotropic actions. In this review, we critically re-evaluate the molecular pharmacology of C. japonicum using an evidence-oriented framework that distinguishes experimentally supported mechanisms from pharmacological associations and emerging hypotheses. Rather than accepting changes in signaling proteins or downstream biomarkers as sufficient evidence of mechanism, we assess the strength of evidence based on reproducibility, pathway-specific interventions, genetic or pharmacological validation, and direct target engagement. Current evidence indicates that nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant responses and nuclear factor kappa B (NF-κB)-associated inflammatory responses represent the most consistently observed pathway associations, although direct molecular targets and causal pathway dependency remain insufficiently established. Evidence for AMPK/PI3K-Akt-associated metabolic regulation and TGF-β/Smad-associated antifibrotic responses is comparatively more limited. In contrast, modulation of apoptosis and autophagy is currently supported primarily by indirect or context-dependent observations. We further discuss how multiple phytochemicals converge on interconnected signaling networks regulating oxidative stress, inflammation, metabolism, tissue remodeling, and cell fate, thereby providing a systems-level explanation for the broad therapeutic potential of C. japonicum. Finally, we highlight the need for standardized phytochemical characterization, rigorous target validation, multi-omics integration, and artificial intelligence-assisted systems biology to establish causal molecular mechanisms and accelerate the translational development of evidence-based phytopharmaceuticals.
- Open Access
- 26 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16  (6) , 779
Correction: Kim, K.-H.; Yoo, B.C. Gintonin as a Lysophosphatidic Acid-Enriched GPCR Ligand System: Molecular Architecture and Receptor Pharmacology in Panax ginseng. Biomolecules 2026, 16, 465
- 26 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16  (6) , 779
Open AccessCorrection: Kim, K.-H.; Yoo, B.C. Gintonin as a Lysophosphatidic Acid-Enriched GPCR Ligand System: Molecular Architecture and Receptor Pharmacology in Panax ginseng. Biomolecules 2026, 16, 465
- Open Access
- 21 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (10) , 4623
Why Targeting Tumor Acidity Fails: Translational Barriers and Emerging Solutions
Tumor acidity is a hallmark of the tumor microenvironment (TME) and has been widely regarded as a promising therapeutic target due to its ubiquity, functional relevance, and apparent selectivity for malignant tissues. Extensive preclinical studies have demonstrated that targeting tumor acidity—through inhibition of lactate production, blockade of proton transport, systemic buffering, and pH-responsive drug delivery—can suppress tumor growth, reduce metastasis, and enhance antitumor immunity. However, despite strong mechanistic rationale and consistent preclinical efficacy, these strategies have failed to achieve meaningful and durable clinical success. In this review, we examine the underlying reasons for this translational discrepancy. We highlight key mechanistic and systemic barriers, including spatial heterogeneity of tumor pH, temporal dynamics and adaptive evolution, metabolic plasticity, redundancy of pH-regulating systems, systemic physiological constraints, and drug delivery limitations in hypoxic and acidic regions. We further argue that tumor acidity is not a sufficient standalone driver of tumor progression but rather a feature of a complex and adaptive system shaped by metabolic and microenvironmental interactions. Finally, we discuss emerging strategies that may overcome these limitations, including combination therapies integrating metabolic targeting with immunotherapy, pH-responsive drug delivery systems, microenvironment reprogramming, and biomarker-guided patient stratification. Overall, current evidence suggests that future therapeutic approaches may benefit more from exploiting tumor acidity as a feature of the tumor microenvironment rather than attempting to directly neutralize it.
- 21 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (10) , 4623
Open AccessWhy Targeting Tumor Acidity Fails: Translational Barriers and Emerging Solutions
Tumor acidity is a hallmark of the tumor microenvironment (TME) and has been widely regarded as a promising therapeutic target due to its ubiquity, functional relevance, and apparent selectivity for malignant tissues. Extensive preclinical studies have demonstrated that targeting tumor acidity—through inhibition of lactate production, blockade of proton transport, systemic buffering, and pH-responsive drug delivery—can suppress tumor growth, reduce metastasis, and enhance antitumor immunity. However, despite strong mechanistic rationale and consistent preclinical efficacy, these strategies have failed to achieve meaningful and durable clinical success. In this review, we examine the underlying reasons for this translational discrepancy. We highlight key mechanistic and systemic barriers, including spatial heterogeneity of tumor pH, temporal dynamics and adaptive evolution, metabolic plasticity, redundancy of pH-regulating systems, systemic physiological constraints, and drug delivery limitations in hypoxic and acidic regions. We further argue that tumor acidity is not a sufficient standalone driver of tumor progression but rather a feature of a complex and adaptive system shaped by metabolic and microenvironmental interactions. Finally, we discuss emerging strategies that may overcome these limitations, including combination therapies integrating metabolic targeting with immunotherapy, pH-responsive drug delivery systems, microenvironment reprogramming, and biomarker-guided patient stratification. Overall, current evidence suggests that future therapeutic approaches may benefit more from exploiting tumor acidity as a feature of the tumor microenvironment rather than attempting to directly neutralize it.
- Open Access
- 15 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (10) , 4438
Circulating Dipeptides in Cancer: Degradation Fragments or Functional Metabolites?
Advances in mass spectrometry-based metabolomics have enabled the detection of numerous small molecules in biological systems, revealing complex metabolic alterations associated with cancer. Among these, dipeptides are consistently detected in plasma, serum, and tumor tissue metabolomic profiles, yet their biological significance is not fully understood. In most studies, circulating dipeptides are interpreted as nonspecific byproducts of protein degradation generated during increased proteolysis. However, accumulating evidence suggests that at least some endogenous dipeptides may have biological activities, including antioxidant effects, metabolic modulation, and potential signaling functions. In this review, we examine the possible origins, transport mechanisms, and biological implications of circulating dipeptides in cancer metabolomics. We discuss multiple sources of dipeptide generation, including intracellular proteolysis, autophagy, extracellular matrix remodeling, tumor cell death, host tissue catabolism, and microbiome metabolism. We also summarize current knowledge regarding peptide transport systems and intracellular dipeptide metabolism that may regulate the fate of these molecules within mammalian systems. In addition, evidence supporting the biological activities of certain endogenous dipeptides is reviewed to evaluate the possibility that some circulating dipeptides may function as bioactive metabolites. Finally, we propose conceptual frameworks for interpreting circulating dipeptides in cancer, including their potential roles as indicators of protein turnover, intermediates in amino acid recycling, stress-buffering molecules, metabolic signals, or components of tumor–host metabolic communication. A better understanding of circulating dipeptides may provide new insights into cancer metabolism and reveal previously overlooked metabolite classes with potential biomarker or functional significance.
- 15 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (10) , 4438
Open AccessCirculating Dipeptides in Cancer: Degradation Fragments or Functional Metabolites?
Advances in mass spectrometry-based metabolomics have enabled the detection of numerous small molecules in biological systems, revealing complex metabolic alterations associated with cancer. Among these, dipeptides are consistently detected in plasma, serum, and tumor tissue metabolomic profiles, yet their biological significance is not fully understood. In most studies, circulating dipeptides are interpreted as nonspecific byproducts of protein degradation generated during increased proteolysis. However, accumulating evidence suggests that at least some endogenous dipeptides may have biological activities, including antioxidant effects, metabolic modulation, and potential signaling functions. In this review, we examine the possible origins, transport mechanisms, and biological implications of circulating dipeptides in cancer metabolomics. We discuss multiple sources of dipeptide generation, including intracellular proteolysis, autophagy, extracellular matrix remodeling, tumor cell death, host tissue catabolism, and microbiome metabolism. We also summarize current knowledge regarding peptide transport systems and intracellular dipeptide metabolism that may regulate the fate of these molecules within mammalian systems. In addition, evidence supporting the biological activities of certain endogenous dipeptides is reviewed to evaluate the possibility that some circulating dipeptides may function as bioactive metabolites. Finally, we propose conceptual frameworks for interpreting circulating dipeptides in cancer, including their potential roles as indicators of protein turnover, intermediates in amino acid recycling, stress-buffering molecules, metabolic signals, or components of tumor–host metabolic communication. A better understanding of circulating dipeptides may provide new insights into cancer metabolism and reveal previously overlooked metabolite classes with potential biomarker or functional significance.
- Open Access
- 2 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (9) , 4089
Why Do Cells Contain Thousands of Lipid Species? Toward an Integrated Framework for Lipid Diversity in Biological Membranes
Cells contain an unexpectedly large diversity of lipid molecules. Modern lipidomics studies have revealed that even a single cell type can harbor hundreds to thousands of distinct lipid species that differ in headgroup structure, acyl chain length, and degree of unsaturation. While this remarkable diversity is now well established, its biological significance remains incompletely understood. Why do cells maintain such complex lipidomes? In this review, we examine several conceptual frameworks that may help explain the origin and functional significance of lipid diversity. First, the physical properties of biological membranes impose constraints on lipid composition, as variations in lipid structure influence membrane fluidity, curvature, thickness, and phase behavior. Second, lipids can regulate membrane protein function through specific interactions and through the physical environment of the lipid bilayer. Third, lipid metabolism generates signaling molecules that participate in diverse regulatory pathways. Fourth, lipid metabolic networks continuously remodel membrane composition, producing dynamic lipidomes that can adapt to physiological conditions. Finally, evolutionary processes have shaped membrane lipid composition across different domains of life, suggesting that lipid diversity may reflect long-term adaptation to functional and environmental constraints. Taken together, these perspectives suggest that lipid diversity is unlikely to be a simple byproduct of metabolism. Instead, the cellular lipidome may emerge from the interplay of membrane biophysics, metabolic network architecture, protein regulation, and evolutionary pressures. Understanding why cells contain thousands of lipid species therefore represents an important challenge for modern cell biology and may reveal fundamental principles governing the organization of biological membranes.
- 2 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (9) , 4089
Open AccessWhy Do Cells Contain Thousands of Lipid Species? Toward an Integrated Framework for Lipid Diversity in Biological Membranes
Cells contain an unexpectedly large diversity of lipid molecules. Modern lipidomics studies have revealed that even a single cell type can harbor hundreds to thousands of distinct lipid species that differ in headgroup structure, acyl chain length, and degree of unsaturation. While this remarkable diversity is now well established, its biological significance remains incompletely understood. Why do cells maintain such complex lipidomes? In this review, we examine several conceptual frameworks that may help explain the origin and functional significance of lipid diversity. First, the physical properties of biological membranes impose constraints on lipid composition, as variations in lipid structure influence membrane fluidity, curvature, thickness, and phase behavior. Second, lipids can regulate membrane protein function through specific interactions and through the physical environment of the lipid bilayer. Third, lipid metabolism generates signaling molecules that participate in diverse regulatory pathways. Fourth, lipid metabolic networks continuously remodel membrane composition, producing dynamic lipidomes that can adapt to physiological conditions. Finally, evolutionary processes have shaped membrane lipid composition across different domains of life, suggesting that lipid diversity may reflect long-term adaptation to functional and environmental constraints. Taken together, these perspectives suggest that lipid diversity is unlikely to be a simple byproduct of metabolism. Instead, the cellular lipidome may emerge from the interplay of membrane biophysics, metabolic network architecture, protein regulation, and evolutionary pressures. Understanding why cells contain thousands of lipid species therefore represents an important challenge for modern cell biology and may reveal fundamental principles governing the organization of biological membranes.
- Open Access
- 29 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (9) , 3971
Beyond Correlation: Constraint Architecture Explains Proteome–Metabolome Decoupling
Multi-omics technologies enable parallel quantification of proteomic and metabolomic layers, yet enzyme abundance often shows weak or nonlinear correspondence under diverse biological conditions. This apparent discordance has been attributed to both technical limitations—such as dynamic range compression in LC-MS/MS, metabolite derivatization artifacts, and missing values in proteomic measurements—as well as intrinsic biological properties of metabolic network architecture. While technical factors contribute to cross-omic mismatch, accumulating evidence suggests that constraint-driven network behavior plays a major role in shaping this decoupling. Enzyme abundance constrains catalytic capacity; however, realized flux is selected within this capacity under distributed flux control, as formalized by flux control coefficients in metabolic control analysis, and is further modulated by enzyme kinetics (e.g., km and Vmax), post-translational modifications, substrate availability, and thermodynamic constraints. Metabolite pools, in turn, reflect the physicochemical state of the system, while specific metabolites can also act as regulatory effectors that modulate enzymatic activity and cellular signaling. Because metabolic networks are underdetermined, multiple flux configurations can satisfy identical protein abundance and metabolite concentration data. Static cross-layer correlation is therefore insufficient for mechanistic inference. We synthesize biological mechanisms—including post-translational regulation, allostery, thermodynamic buffering, spatial compartmentalization, feedback amplification, and redox gating—that weaken linear abundance–metabolite expectations. We further outline a constraint-based interpretation framework in which proteomics imposes capacity bounds, metabolomics informs reaction directionality and metabolite pool constraints, and flux-informed approaches reduce solution degeneracy by providing additional information on pathway activity. Moving beyond correlation requires integrating perturbation, temporal resolution, and constraint-aware modeling. Proteome–metabolome discordance should therefore be interpreted not as inconsistency, but as indicative of constraint-driven state selection within high-dimensional biochemical systems.
- 29 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (9) , 3971
Open AccessBeyond Correlation: Constraint Architecture Explains Proteome–Metabolome Decoupling
Multi-omics technologies enable parallel quantification of proteomic and metabolomic layers, yet enzyme abundance often shows weak or nonlinear correspondence under diverse biological conditions. This apparent discordance has been attributed to both technical limitations—such as dynamic range compression in LC-MS/MS, metabolite derivatization artifacts, and missing values in proteomic measurements—as well as intrinsic biological properties of metabolic network architecture. While technical factors contribute to cross-omic mismatch, accumulating evidence suggests that constraint-driven network behavior plays a major role in shaping this decoupling. Enzyme abundance constrains catalytic capacity; however, realized flux is selected within this capacity under distributed flux control, as formalized by flux control coefficients in metabolic control analysis, and is further modulated by enzyme kinetics (e.g., km and Vmax), post-translational modifications, substrate availability, and thermodynamic constraints. Metabolite pools, in turn, reflect the physicochemical state of the system, while specific metabolites can also act as regulatory effectors that modulate enzymatic activity and cellular signaling. Because metabolic networks are underdetermined, multiple flux configurations can satisfy identical protein abundance and metabolite concentration data. Static cross-layer correlation is therefore insufficient for mechanistic inference. We synthesize biological mechanisms—including post-translational regulation, allostery, thermodynamic buffering, spatial compartmentalization, feedback amplification, and redox gating—that weaken linear abundance–metabolite expectations. We further outline a constraint-based interpretation framework in which proteomics imposes capacity bounds, metabolomics informs reaction directionality and metabolite pool constraints, and flux-informed approaches reduce solution degeneracy by providing additional information on pathway activity. Moving beyond correlation requires integrating perturbation, temporal resolution, and constraint-aware modeling. Proteome–metabolome discordance should therefore be interpreted not as inconsistency, but as indicative of constraint-driven state selection within high-dimensional biochemical systems.
- Open Access
- 28 April 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1806328
Green tea–derived exosome-like nanoparticles attenuate oxidative stress–induced skin senescence via modulation of p38 MAPK signaling
Introduction: Plant-derived exosome-like nanoparticles (PDENs) have emerged as bioactive nanostructures capable of transferring molecular cargos across species; however, their mechanistic roles in mammalian stress-responsive signaling remain incompletely defined. In this study, we investigated the effects of green tea ( Camellia sinensis (L.) Kuntze [Theaceae])–derived exosome-like nanoparticles (GtDENs) on oxidative stress–induced cellular dysfunction in human keratinocytes. Methods: To do this, we employed MTT assay, immunoblotting analysis, real-time PCR method, SA-beta-gal assay, flowcytometry, and molecular docking model. Results and Discussion: GtDENs exhibited no detectable cytotoxicity and significantly attenuated hydrogen peroxide– and UVB-induced reactive oxygen species (ROS) accumulation and cell death. GtDENs suppressed oxidative stress–associated cellular senescence and apoptotic gene expression, including MMP3, p21, and caspases. Mechanistically, GtDENs preferentially reduced phosphorylation of p38 MAPK and downstream c-Fos activation under oxidative stress conditions, while ERK and JNK signaling remained largely unaffected. Functional analyses, including p38 overexpression and pharmacological inhibition experiments, support the involvement of p38 MAPK signaling in mediating GtDEN activity. Phytochemical profiling identified caffeine as the predominant small-molecule component within GtDENs. Molecular docking and cellular thermal shift assays suggest potential interaction between caffeine and p38 MAPK, although direct biochemical binding validation was not performed. Exploratory small RNA profiling further indicated the presence of regulatory RNA species associated with stress-responsive pathways. Collectively, these findings indicate that GtDENs modulate oxidative stress–responsive signaling, with p38 MAPK emerging as a key signaling axis involved in this response.
- 28 April 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1806328
Open AccessGreen tea–derived exosome-like nanoparticles attenuate oxidative stress–induced skin senescence via modulation of p38 MAPK signaling
Introduction: Plant-derived exosome-like nanoparticles (PDENs) have emerged as bioactive nanostructures capable of transferring molecular cargos across species; however, their mechanistic roles in mammalian stress-responsive signaling remain incompletely defined. In this study, we investigated the effects of green tea ( Camellia sinensis (L.) Kuntze [Theaceae])–derived exosome-like nanoparticles (GtDENs) on oxidative stress–induced cellular dysfunction in human keratinocytes. Methods: To do this, we employed MTT assay, immunoblotting analysis, real-time PCR method, SA-beta-gal assay, flowcytometry, and molecular docking model. Results and Discussion: GtDENs exhibited no detectable cytotoxicity and significantly attenuated hydrogen peroxide– and UVB-induced reactive oxygen species (ROS) accumulation and cell death. GtDENs suppressed oxidative stress–associated cellular senescence and apoptotic gene expression, including MMP3, p21, and caspases. Mechanistically, GtDENs preferentially reduced phosphorylation of p38 MAPK and downstream c-Fos activation under oxidative stress conditions, while ERK and JNK signaling remained largely unaffected. Functional analyses, including p38 overexpression and pharmacological inhibition experiments, support the involvement of p38 MAPK signaling in mediating GtDEN activity. Phytochemical profiling identified caffeine as the predominant small-molecule component within GtDENs. Molecular docking and cellular thermal shift assays suggest potential interaction between caffeine and p38 MAPK, although direct biochemical binding validation was not performed. Exploratory small RNA profiling further indicated the presence of regulatory RNA species associated with stress-responsive pathways. Collectively, these findings indicate that GtDENs modulate oxidative stress–responsive signaling, with p38 MAPK emerging as a key signaling axis involved in this response.
- Open Access
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (9) , 3889
The Abundance Paradox of S100A8/A9 in Neutrophils: Functional Logic of Calprotectin Dominance in the Cytosolic Proteome
Neutrophils are the most abundant circulating leukocytes and are characterized by a proteome in which granule-associated proteins synthesized during granulopoiesis constitute a major fraction of total cellular protein, reflecting their preloaded effector nature in innate immune defense. A striking feature of neutrophil biology is the unusual abundance of the calcium-binding proteins S100A8 and S100A9, which together form the heterodimeric complex known as calprotectin. Early biochemical studies estimated that S100A8/A9 constitutes a substantial fraction of the soluble cytosolic proteome in neutrophils, with later studies often describing it as one of the most abundant protein complexes in these cells. Despite extensive studies on the antimicrobial and inflammatory activities of calprotectin, the biological rationale for this unusual abundance remains incompletely understood. In this review, we examine the structural, biochemical, and regulatory features of S100A8/A9 and explore the potential explanations for its high abundance in the neutrophil cytosol. We first discuss the unique organization of the neutrophil proteome and the transcriptional programs governing granulopoiesis that lead to large-scale production of neutrophil effector proteins. We then review the structural and biochemical properties of S100A8/A9, including its calcium-dependent conformational dynamics and high-affinity transition metal binding, which contribute to antimicrobial defense through nutritional immunity. Several functional hypotheses are considered to explain calprotectin abundance, including roles as an antimicrobial reservoir, a metal-sequestering molecule, a regulator of oxidative stress, and a source of damage-associated molecular patterns. Finally, we discuss the evolutionary logic of neutrophil protein preloading and the implications of calprotectin biology in inflammatory diseases and the tumor microenvironment. Resolving the abundance paradox of S100A8/A9 may reveal fundamental principles governing the organization of innate immune cell proteomes and provide new insights into the strategies used by neutrophils to achieve rapid and effective host defense.
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (9) , 3889
Open AccessThe Abundance Paradox of S100A8/A9 in Neutrophils: Functional Logic of Calprotectin Dominance in the Cytosolic Proteome
Neutrophils are the most abundant circulating leukocytes and are characterized by a proteome in which granule-associated proteins synthesized during granulopoiesis constitute a major fraction of total cellular protein, reflecting their preloaded effector nature in innate immune defense. A striking feature of neutrophil biology is the unusual abundance of the calcium-binding proteins S100A8 and S100A9, which together form the heterodimeric complex known as calprotectin. Early biochemical studies estimated that S100A8/A9 constitutes a substantial fraction of the soluble cytosolic proteome in neutrophils, with later studies often describing it as one of the most abundant protein complexes in these cells. Despite extensive studies on the antimicrobial and inflammatory activities of calprotectin, the biological rationale for this unusual abundance remains incompletely understood. In this review, we examine the structural, biochemical, and regulatory features of S100A8/A9 and explore the potential explanations for its high abundance in the neutrophil cytosol. We first discuss the unique organization of the neutrophil proteome and the transcriptional programs governing granulopoiesis that lead to large-scale production of neutrophil effector proteins. We then review the structural and biochemical properties of S100A8/A9, including its calcium-dependent conformational dynamics and high-affinity transition metal binding, which contribute to antimicrobial defense through nutritional immunity. Several functional hypotheses are considered to explain calprotectin abundance, including roles as an antimicrobial reservoir, a metal-sequestering molecule, a regulator of oxidative stress, and a source of damage-associated molecular patterns. Finally, we discuss the evolutionary logic of neutrophil protein preloading and the implications of calprotectin biology in inflammatory diseases and the tumor microenvironment. Resolving the abundance paradox of S100A8/A9 may reveal fundamental principles governing the organization of innate immune cell proteomes and provide new insights into the strategies used by neutrophils to achieve rapid and effective host defense.